Journal article
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Abstract
BACKGROUND: Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselkumab in patients with active psoriatic arthritis.
METHODS: We did a randomised, double-blind, placebo-controlled, phase 2a trial at 34 …
Authors
Deodhar A; Gottlieb AB; Boehncke W-H; Dong B; Wang Y; Zhuang Y; Barchuk W; Xu XL; Hsia EC; Group CS
Journal
The Lancet, Vol. 391, No. 10136, pp. 2213–2224
Publisher
Elsevier
Publication Date
June 2018
DOI
10.1016/s0140-6736(18)30952-8
ISSN
0140-6736